Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: A systematic review

BMJ Open

Volumn 6, Issue 6, 2016, Pages

  Mercieca Bebber, Rebecca ^a,b   Palmer, Michael J ^c   Brundage, Michael ^c   Calvert, Melanie ^d   Stockler, Martin R ^a,b   King, Madeleine T ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c QUEEN S UNIVERSITY   (Canada)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CINAHL; CLINICAL RESEARCH; DOCTOR PATIENT RELATION; HUMAN; MEDLINE; QUALITY CONTROL; RESPONSIBILITY; SYNTHESIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; PATIENT-REPORTED OUTCOME; QUALITY OF LIFE;

HUMANS; PATIENT REPORTED OUTCOME MEASURES; QUALITY OF LIFE;

EID: 84975256275     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-010938     Document Type: Article

References (70)

1. Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015;26:1547-73
2. Food and Drug Administration. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. FDA, 2009. http://www.fda. gov/downloads/Drugs/. . . /Guidances/UCM193282. pdf (accessed 10 Mar 2014)
3. European Medicines Agency. Oncology Working Party. Draft Reflection Paper on the use of patient reported outcome (PRO) measures in oncology studies. EMA, 2014. http://www.ema. europa. eu/docs/en-GB/document-library/Scientific-guideline/2014/06/WC500168852. pdf (accessed 2 Sept 2014)
4. Little RJ, D'Agostino R, Cohen ML, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med 2012;367:1355-60
5. Bernhard J, Cella DF, Coates AS, et al. Missing quality of life data in cancer clinical trials: serious problems and challenges. Stat Med 1998;17:517-32
6. Staquet M, Berzon R, Osoba D, et al. Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res 1996;5:496-502
7. Bernhard J, Gelber RD, Hürny C. Preface. Stat Med 1998;17:511-12
8. Bylicki O, Gan HK, Joly F, et al. Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy. Ann Oncol 2015;26:231-7
9. Efficace F, Fayers P, Pusic A, et al. Quality of patient-reported outcome reporting across cancer randomized controlled trials according to the CONSORT patient-reported outcome extension: A pooled analysis of 557 trials. Cancer 2015;121:3335-42
10. Fielding S, Maclennan G, Cook JA, et al. A review of RCTs in four medical journals to assess the use of imputation to overcome missing data in quality of life outcomes. Trials 2008;9:51
11. Friedlander M, Mercieca-Bebber RL, King MT. Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned. Ann Oncol 2016;27(Suppl 1):i66-71
12. Fairclough DL, Peterson HF, Cella D, et al. Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials. Stat Med 1998;17:781-96
13. Fairclough DL, Peterson HF, Chang V. Why are missing quality of life data a problem in clinical trials of cancer therapy? Stat Med 1998;17:667-77
14. Bell ML, Fiero M, Horton NJ, et al. Handling missing data in RCTs; a review of the top medical journals. BMC Med Res Methodol 2014;14:118
15. Rubin DB. Inference and missing data. Biometrika 1976;63:581-92
16. Tabachnick B, Fidell L. Using multivariate statistics. Needham Heights, MA: Allyn & Bacon, 2012
17. Bell ML, Fairclough DL. Practical and statistical issues in missing data for longitudinal patient-reported outcomes. Stat Methods Med Res 2014;23:440-59
18. Curran D, Bacchi M, Schmitz SFH, et al. Identifying the types of missingness in quality of life data from clinical trials. Stat Med 1998;17:739-56
19. Dong Y, Peng CY. Principled missing data methods for researchers. Springerplus 2013;2:222
20. Curran D, Molenberghs G, Fayers PM, et al. Incomplete quality of life data in randomized trials: missing forms. Stat Med 1998;17:697-709
21. Fielding S, Fayers PM, Ramsay CR. Investigating the missing data mechanism in quality of life outcomes: A comparison of approaches. Health Qual Life Outcomes 2009;7:57
22. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009;6:e1000097
23. Barnett-Page E, Thomas J. Methods for the synthesis of qualitative research: A critical review. BMC Med Res Methodol 2009;9:59
24. Gale NK, Heath G, Cameron E, et al. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol 2013;13:117
25. Land SR, Ritter MW, Costantino JP, et al. Compliance with patient-reported outcomes in multicenter clinical trials: methodologic and practical approaches. J Clin Oncol 2007;25:5113-20
26. Cella DF, Lloyd SR. Data collection strategies for patient-reported information. Qual Manag Health Care 1994;2:28-35
27. Fallowfield LJ, Harper P. Health-related quality of life in patients undergoing drug therapy for advanced non-small-cell lung cancer. Lung Cancer 2005;48:365-77
28. Little RJ, Cohen ML, Dickersin K, et al. The design and conduct of clinical trials to limit missing data. Stat Med 2012;31: 3433-43
29. Walker M, Brown J, Brown K, et al. Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma. J Neurooncol 2003;63:179-86
30. Taphoorn MJ, Sizoo EM, Bottomley A. Review on quality of life issues in patients with primary brain tumors. Oncologist 2010;15:618-26
31. Aaronson NK. Quality of life research in cancer clinical trials: A need for common rules and language. Oncology (Williston Park, NY) 1990;4:59-66
32. Young T, de Haes D, Curran D, et al. Guidelines for assessing Quality of Life in EORTC clinical trials. Brussels: EORTC QOL Group, 2002
33. Fallowfield L. Compliance issues in quality of life assessment: experiences of two Cancer Research Campaign sponsored groups. Stat Med 1998;17:541-6
34. Larkin ME, Lorenzi GM, Bayless M, et al. Evolution of the study coordinator role: the 28-year experience in Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC). Clin Trials 2012;9:418-25
35. Bernhard J, Gusset H, Hürny C. Practical issues in quality of life assessment in multicentre trials conducted by the Swiss Group for Clinical Cancer Research. Stat Med 1998;17:633-9
36. Ganz PA, Day R, Costantino J. Compliance with quality of life data collection in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial. Stat Med 1998;17:613-22
37. Wisniewski SR, Leon AC, Otto MW, et al. Prevention of missing data in clinical research studies. Biol Psychiatry 2006;59:997-1000
38. Bernhard J, Peterson HF, Coates AS, et al. Quality of life assessment in International Breast Cancer Study Group (IBCSG) trials: practical issues and factors associated with missing data. Stat Med 1998;17:587-601
39. Hahn EA, Webster KA, Cella D, et al. Missing data in quality of life research in Eastern Cooperative Oncology Group (ECOG) clinical trials: problems and solutions. Stat Med 1998;17:547-59
40. Cella DF. Methods and problems in measuring quality of life. Support Care Cancer 1995;3:11-22
41. Wilcox S, Shumaker SA, Bowen DJ, et al. Promoting adherence and retention to clinical trials in special populations: A women's health initiative workshop. Control Clin Trials 2001;22:279-89
42. Young T, Maher J. Collecting quality of life data in EORTC clinical trials-what happens in practice? Psychooncology 1999;8:260-3
43. Osoba D, Dancey J, Zee B, et al. Health-related quality-of-life studies of the National Cancer Institute of Canada Clinical Trials Group. J Natl Cancer Inst. 1996; Monographs 2: 107-111
44. Hellard ME, Sinclair MI, Forbes AB, et al. Methods used to maintain a high level of participant involvement in a clinical trial. J Epidemiol Community Health 2001;55:348-51
45. Revicki D, Fairclough D. Preventing missing data. In: Fayers P, Hays R, eds. Assessing quality of life in clinical trials: Analysis and interpretation. 2nd edn. Oxford University Press, 2005:209-222
46. Scott RB, Farmer E, Smiton A, et al. Methodology of neuropsychological research in multicentre randomized clinical trials: A model derived from the International Subarachnoid Aneurysm Trial. Clin Trials 2004;1:31-9
47. Hayden KA, Moinpour CM, Metch B, et al. Pitfalls in quality-of-life assessment: lessons from a Southwest Oncology Group breast cancer clinical trial. Oncol Nurs Forum 1993;20:1415-19
48. Rouette J, Blazeby J, King M, et al. Integrating health-related quality of life findings from randomized clinical trials into practice: An international study of oncologists' perspectives. Qual Life Res 2015;24:1317-25
49. Calvert M, Blazeby J, Altman DG, et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 2013;309:814-22
50. Brundage M, Bass B, Davidson J, et al. Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. Qual Life Res 2011;20:653-64
51. Mercieca-Bebber RL, Perreca A, King M, et al. Patient-reported outcomes in head and neck and thyroid cancer randomised controlled trials: A systematic review of completeness of reporting and impact on interpretation. Eur J Cancer 2016;56:144-61
52. Schandelmaier S, Conen K, von Elm E, et al. Planning and reporting of quality-of-life outcomes in cancer trials. Ann Oncol 2015;26:1966-73
53. Glasziou P, Altman DG, Bossuyt P, et al. Reducing waste from incomplete or unusable reports of biomedical research. Lancet 2014;383:267-76
54. Palmer M, Mercieca-Bebber R, King M, et al. A framework for classifying root causes of missing data for patient reported outcomes in prospective studies. Qual Life Res 2015;24:a2016
55. Juni P, Holenstein F, Sterne J, et al. Direction and impact of language bias in meta-analyses of controlled trials: empirical study. Int J Epidemiol 2002;31:115-23
56. Moher D, Pham B, Klassen TP, et al. What contributions do languages other than English make on the results of meta-analyses? J Clin Epidemiol 2000;53:964-72
57. Fairclough D. Design and analysis of quality of life studies in clinical trials. New York: Chapman & Hall, 2010
58. King MT. A point of minimal important difference (MID): A critique of terminology and methods. Expert Rev Pharmacoecon Outcomes Res 2011;11:171-84
59. Wyrwich KW, Nienaber NA, Tierney WM, et al. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care 1999;37:469-78
60. Calvert M, Kyte D, Duffy H, et al. Patient reported outcome (PRO) assessment in clinical trials: A systematic review of guidance for trial protocol writers. PLoS ONE 2014;9:e110216
61. Kyte D, Duffy H, Fletcher B, et al. Systematic evaluation of the patient reported outcome (PRO) content of clinical trial protocols. PLoS ONE 2014;9:e110229
62. Brundage M, Blazeby J, Revicki D, et al. Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. Qual Life Res 2013;22:1161-75
63. Calvert M, Kyte D, von Hildebrand M, et al. Putting patients at the heart of health-care research. Lancet 2015;385: 1073-4
64. Tang ST, McCorkle R. Use of family proxies in quality of life research for cancer patients at the end of life: A literature review. Cancer Invest 2002;20:1086-104
65. Gheorghe A, Roberts T, Hemming K, et al. Evaluating the generalisability of trial results: introducing a centre-and trial-level generalisability index. Pharmacoeconomics 2015;33:1195-214
66. Rutherford C, Costa D, Mercieca-Bebber R, et al. Mode of administration does not cause bias in patient-reported outcome results: A meta-analysis. Qual Life Res 2015;3:3
67. Cantrell MA, Lupinacci P. Methodological issues in online data collection. J Adv Nurs 2007;60:544-9
68. Edwards P, Roberts I, Clarke M, et al. Methods to increase response rates to postal questionnaires. Cochrane Database Syst Rev 2007; (2):MR000008
69. Osoba D, Bezjak A, Brundage M, et al. Evaluating health-related quality of life in cancer clinical trials: the National Cancer Institute of Canada Clinical Trials Group experience. Value Health 2007;10 (Suppl 2):S138-45
70. Osoba D, Bezjak A, Brundage M, et al. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2005;41:280-7.